Are there generic versions of Ripretinib?

Currently, there are no generic drugs of Ripretinib produced and marketed overseas. The U.S. Food and Drug Administration (FDA) approved Ripretinib to treat adult patients with advanced gastrointestinal stromal tumors who have been previously treated with three or more kinase inhibitors, including imatinib. Originally known as DCC-2618 and now under the trade name Qinlock, repetitinib was developed by Deciphera Pharmaceuticals to inhibit primary and drug-resistant secondary KIT and PDGFRA mutations. It is effective and safe as a fourth (or further) line of therapy in patients with advanced gastrointestinal stromal tumors.